342
Participants
Start Date
March 12, 2021
Primary Completion Date
February 1, 2029
Study Completion Date
February 1, 2029
Atezolizumab
Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until participant experience loss of clinical benefit as evaluated by the investigator or unacceptable toxicity or withdrawal of informed consent.
Becavizumab
Bevacizumab will be administered by IV infusion at a fixed dose of 15 mg/kg on Day 1 of each 21-day Cycle.
Transarterial chemoembolization (TACE)
TACE will be performed by clinical demand.
Peking University First Hospital, Beijing
Peking University People's Hospital, Beijing
Beijing You An Hospital, Beijing
Beijing Tsinghua Changgung Hospital, Beijing
Shengjing Hospital of China Medical University, Shenyang
The 900th Hospital of PLA joint service support force, Fuzhou
Harbin Medical University Cancer Hospital, Harbin
Fudan University Shanghai Cancer Center, Shanghai
Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai
Jiangsu Cancer Hospital, Nanjing
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing
Anhui Provincial Hospital, Anhui
Tianjin Cancer Hospital, Tianjin
Zhejiang Cancer Hospital, Hangzhou
The First Affiliated Hospital Of Fujian Medical University, Fuzhou
Fujian Cancer Hospital, Fuzhou
Mengchao Hepatobiliary Hospital Of Fujian Medical University, Fuzhou
The First Affiliated Hospital, Chongqing Medical University, Chongqing
Southwest Hospital , Third Military Medical University, Chongqing
Hunan Cancer Hospital, Changsha
Henan Cancer Hospital, Zhengzhou
Sun Yet-sen University Cancer Center, Guangzhou
Nanfang Hospital, Southern Medical University, Guangzhou
Zhuhai People's Hospital, Zhuhai
Guangxi Cancer Hospital of Guangxi Medical University, Nanning
The First Affiliate Hospital of Guangxi Medical University, Nanning
West China Hospital, Sichuan University, Chengdu
Zhongshan Hospital Fudan Unvierstiy, Shanghai
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an
Xi'an Inernational Medical Center Hospital, Xi'an
Aichi Cancer Center, Aichi
Chiba University Hospital, Chiba
Kurume University Hospital, Fukuoka
Hiroshima University Hospital, Hiroshima
Yokohama City University Medical Center, Kanagawa
Kanagawa Cancer Center, Kanagawa
Kitasato University Hospital, Kanagawa
The University of Osaka Hospital, Osaka
Kindai University Hospital, Osaka
Toranomon Hospital, Tokyo
Hoffmann-La Roche
INDUSTRY